This application is submitted in response to RFA AI-94-010. We propose to establish a consortium of laboratories to co-ordinate virological, immunological, molecular biological, and genetic investigations of the biological basis of progression of HIV infection from seroconversion to AIDS. This will be done using the clinical and repository resources of the Multicenter AIDS Cohort Study (MACS). Specifically, in order to identify the immunologic and virologic mechanisms which may be involved in progression to disease or in long-term stability and non-progression, we propose to perform concurrent and non-concurrent prospective cohort studies of three groups of HIV+ MACS participants, who have been selected because of their different clinical responses to HIV infection: 1) no decline of CD4+ lymphocytes (i.e., counts > 8O0/microliters) despite at least 10 years of HIV infection (high stable group), 2) stable CD4+ lymphocyte counts for 4-5 years after an initial moderate decline to the range of 350-500/microliters (low stable group) and 3) recent seroconverters with CD4+ lymphocyte levels similar to group I now but likely to decline significantly during the study period. Using specimens collected from these study participants every 3 months (in the concurrent prospective study) or every 6 months (in the nonconcurrent prospective study), we will test the hypotheses that 1) viral load and genetic diversity, as well as host genetics and immune response to HIV, early in the infection have a major impact on the rate of progression of HIV disease; 2) low viral load and disease stability are maintained by cytotoxic T lymphocytes and other immunological effector mechanisms; and 3) a final common pathway of disease progression begins approximately 2 years prior to AIDS. These hypotheses will be tested by measuring viral load (i.e., levels of unspliced (gag) RNA in PBMC and plasma measured by quantitative PcR, and proviral DNA PBMC by quantitative PCR and in situ PCR), viral genetic diversity and phenotypic variation (measured by heteroduplex mobility assay and heteroduplex tracking assay), host immune response (activity of effector and memory cytotoxic T lymphocytes (CTL), CD8+ lymphocyte-mediated suppression of HIV replication, and neutralizing antibodies against autologous viruses. These critical data will be correlated with progression of disease (decline or stability of CD4+ lymphocyte counts, development of HIV-related symptoms) of the subjects studied. The data obtained, and the repository which will be established of biological samples, HIV isolates, and other materials, will be important in unraveling the mechanisms by which some HIV+ gay men are able to prevent progression of HIV disease, and thus will be important for development of drugs and vaccines against HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI037984-01
Application #
2074895
Study Section
Special Emphasis Panel (SRC (70))
Project Start
1995-04-01
Project End
1999-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Tipton, Laura; Cuenco, Karen T; Huang, Laurence et al. (2018) Measuring associations between the microbiota and repeated measures of continuous clinical variables using a lasso-penalized generalized linear mixed model. BioData Min 11:12
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Drozd, Daniel R; Kitahata, Mari M; Althoff, Keri N et al. (2017) Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr 75:568-576
Dubrow, Robert; Qin, Li; Lin, Haiqun et al. (2017) Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr 75:382-390
Jiamsakul, Awachana; Kariminia, Azar; Althoff, Keri N et al. (2017) HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration. J Acquir Immune Defic Syndr 76:319-329

Showing the most recent 10 out of 231 publications